newsfilter
← Earnings
Earnings Releases·

Corcept Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue surged 64% year-over-year to $340.5 million, driven by a 92% quarter-over-quarter increase in Lifyorli revenue to $91.4 million and a 19% rise in Korlym sales to $249.1 million; net income jumped to $126.8 million from $19.7 million in Q3 2025.
  • The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion and expects FDA approval for relacorilant in Cushing's syndrome by December 17, 2026, alongside European Commission approval for relacorilant in ovarian cancer by year-end.
  • Strategic pipeline progress includes an 84% reduction in death risk for dazucorilant in ALS, positive MONARCH study data for miricorilant in MASH, and plans to initiate a Phase 3 ALS trial next year and a Phase 2 miricorilant trial soon.
  • Capital allocation included the repurchase of $43.7 million in common stock during the quarter, while cash and investments grew by $117.7 million to $662.3 million.
Company
CORCEPT THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology